Chemical Nametedizolid phosphate
Dosage FormInjection/Tablet (intravenous/oral; 200mg/200mg)
Drug ClassAntibacterials
CompanyMerck & Co.
Approval Year2014


  • For the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.
Last updated on 4/20/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sivextro (tedizolid phosphate) Prescribing Information2014Cubist Pharmaceuticals U.S., Lexington, MA